Mentions
Extended reach
Total likes
Video views
AI synopsis
In several discussions, users highlight the overall survival benefits and improved progression-free survival rates associated with the combination treatment of atezolizumab and bevacizumab as mentioned in the publication. Phrases like 'game changer' and 'new standard of care' reinforce the transformative potential of this treatment, while questions regarding the methodology suggest a critical engagement with the research. The tone remains optimistic overall, contributing to a sense of urgency and importance around adopting these findings in clinical practice.
The majority of discussions express strong agreement with the findings and implications of the study, reflecting a consensus on its importance in treatment.
Many participants show a high level of interest in the article, as evident from the volume of related posts and their eagerness to discuss various aspects of the research.
While there is significant interaction, some posts reflect a more surface-level engagement, focusing on sharing information rather than delving deeply into analysis.
The discussions indicate that users perceive the publication as having a considerable influence on treatment standards for hepatocellular carcinoma.
For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al. Expert opinion: @SeragHashem Moderators: @AtoosaRabiee @jturnesv https://t.co/TrdwCejYKI #livertwitter #GIJC #hpbcsm
What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #GIJC discussion on @NEJM article https://t.co/D1TGKgxiZX. Special thanks to @AtoosaRabiee @LizzieAbyMD @jturnesv @SeragHashem https://t.co/g6TMCl7eeU
Disruptive Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma by @GABOUALFA @practiceupdate available at: https://t.co/UC0GCKvpg6.
⭐️ Conclusions ⭐️ Atezolizumab plus bevacizumab (vs sorafenib) resulted in significantly better overall survival and progression free survival in patients w/unresectable HCC without prior systemic treatment https://t.co/TrdwCejYKI #GIJC #livertwitter
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? https://t.co/pbylwGhQaQ
New standard of care for advanced HCC patients! @NEJM #movingforward #hope Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/UHm5cYtRxN
This video discusses the combination of atezolizumab and bevacizumab, which demonstrated promising anti-cancer effects in patients with unresectable hepatocellular carcinoma during a phase 1b trial, leading to improved…
Hepatobiliary cancer presents significant treatment challenges. This video explores the combination of atezolizumab and bevacizumab, which showed improved survival rates in patients with unresectable hepatocellular…
@JacobPlieth @ApexOnco Where are these numbers from? Original publication sais 27% ORR and mPFS of 6.9 months https://t.co/HctXluRuTp
Here's a similar article in HCC. Naturally, the combo of Atezo-Bev may result in PFS “improvements”by concealing progression. Alternative endpoints to PFS are necessary for a clearer understanding. It's time for more rigorous standards @JAMAOnc @NEJM. https://t.co/2N5u0ALdR1
@8thKingofRome The bars for $AFMD 24+PD-L1 look the same Median progression-free survival was 6.8 months (95% CI, 5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups Grade 3 or 4 hypertension occurred in 15.2% of patients https://t.co/uFZ68b9byP
Combining a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82) https://t.co/CCw3ieCLwT https://t.co/xpboKlTPrZ
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/uDoKzkqKRJ
RT @KrishanJethwa: Follow-up Trial to IMBrave 150 advanced/metastatic HCC https://t.co/odYxOwflfq #ASCO23 #ASCO2023 https://t.co/aXO6dV1P…
RT @KrishanJethwa: Follow-up Trial to IMBrave 150 advanced/metastatic HCC https://t.co/odYxOwflfq #ASCO23 #ASCO2023 https://t.co/aXO6dV1P…
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma #ASCO23 https://t.co/eUxkPnXG2U
Follow-up Trial to IMBrave 150 advanced/metastatic HCC https://t.co/odYxOwflfq #ASCO23 #ASCO2023 https://t.co/aXO6dV1Pud
@tstamm7002 @Biohazard3737 Yeah, seems so and n=18 Phase 3 atezo + bev mPFS was 6.8mos In Phase 1b ORR was 36% and mPFS 7 mos https://t.co/aZOjui7ipM
RT @5_utr: @jryckman3 @KrishanJethwa @free_radical28 @nbn426 @NiuSanford @lauren_henke @ldawsonmd @j_lukovic HR for death with atezolizumab…
@jryckman3 @KrishanJethwa @free_radical28 @nbn426 @NiuSanford @lauren_henke @ldawsonmd @j_lukovic HR for death with atezolizumab-bevacizumab vs sorafenib was 0.58 (0.42 to 0.79; P<0.001) If SBRT > sorafenib, atezo/bev > sorafenib, TARE NOT > sorafenib, makes to examine SBRT, atezo/bev and drop TARE https://t.co/9vurffHjxg
RT @casadei_gardini: Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the…
RT @casadei_gardini: Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the…
RT @casadei_gardini: Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the…
RT @casadei_gardini: Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the…
RT @casadei_gardini: Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the…
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? https://t.co/pbylwGhQaQ
@EstesRadonc @MaryFengMD had a great slide comparing RTOG1112 to the atezo + bev regimen from IMbrave150 that led to termination. RTOG1112: OS 12.3 -> 15.8 mo, PFS 5.5 -> 9.2 mo IMbrave: OS 13.4 -> 19.2 mo, PFS 4.3 -> 6.9 mo Atezo + bev +/- SBRT trial proposed now. https://t.co/GcFhioiKHY
#ESMO22 #Hepatocellular Grade 3 or higher TRAE was relatively high (80.9% vs. 52.4%) for #camrelizumab+#rivoceranib. Grade 3 or 4 events in the #IMbrave150 study were similar between #atezolizumab+#bevacizumab and #sorafenib. https://t.co/mHyKAr4SXD https://t.co/1wwDvuH4d5
#clinicaltrial Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma https://t.co/kGR2zSx09n
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: Status: Not yet recruiting, Condition Summary: Hepatocellular Carcinoma https://t.co/DvHdfvlLdd
RT @PaperbirdsO: New clinical trial: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Ate…
New clinical trial: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma https://t.co/N3GkXvC3d9 #livercancer #oncology https://t.co/UQPXYdkqS0
A decade of clinical trials were unable to improve on the survival benefit with sorafenib until lenvatinib demonstrated non-inferiority in the REFLECT trial. Finally, in 2020 atezolizumab/bev significantly improved OS over sorafenib in IMBrave150 https://t.co/1947gqq3Ve 3/
RT @MLPOncoData: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma https://t.co/MWsK4kFFAG
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma https://t.co/MWsK4kFFAG
https://t.co/c8KHGC9R26 In this Phase 3 trial (N=501), Atelzolizumab + Bevacizumab was associated with significantly improved overall survival and progression-free survival than Sorafenib in pts with unresectable HCC who had received no previous systemic treatment
ادارة الغذاء والدواء الامريكية توافق على خط علاجي اول للمرضى الذين تم تشخيصهم حديثًا بسرطان الخلايا الكبدية.
RT @DenboJw: Very exciting. Over the last couple of years in liver tumor board, we have switched to recommending atezo/bev for locally adva…
RT @DenboJw: Very exciting. Over the last couple of years in liver tumor board, we have switched to recommending atezo/bev for locally adva…
RT @DenboJw: Very exciting. Over the last couple of years in liver tumor board, we have switched to recommending atezo/bev for locally adva…
Very exciting. Over the last couple of years in liver tumor board, we have switched to recommending atezo/bev for locally advanced HCC instead of liver-directed therapy. https://t.co/lzE4rIUa6C @DanielAnayaMD @MHepatobiliary @EricHJensenMD @liver_cancer https://t.co/pnVc0ad6vG
肝細胞癌(HCC) https://t.co/9qICBHvw3K
The first choice of drug therapy in HCC is Atezolizumab+Bev. Treatment is changing rapidly
RT @DanengLi: Honored to have helped to bring a new standard of care to HCC patients. @NEJM @genentech https://t.co/XYSLL7DTtB
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
@AmyOxentenkoMD @AllonKahn @DCharabaty @SophieBalzoraMD @BrennanSpiegel @PopovVioleta @MLongMD @LindaNguyenMD @AasmaShaukatMD @BilalMohammadMD Meant to reply but quote tweeted instead! A) Semaglutide for nash https://t.co/FXlBoiiC2c , B) #fmt for #alcohol https://t.co/mjCPhiOsHT, C) #HCC treatment first-line https://t.co/ulQuLoyXTn
One more!! Hepatocellular cancer now first line Rx https://t.co/ulQuLoyXTn https://t.co/aiJRIAgEls
7/Dr. Kizub discussed the results of the IMbrave 150 trial, evaluating atezo/bev in unresectable HCC. This is now a FDA approved ✅ SOC regimen for the 1L treatment of advanced unresectable HCC #hccsm
#YearinReview TOP PICK - Combination of atezolizumab (anti-PDL1 monoclonal antibody) and bevacizumab (anti-VEGF monoclonal antibody) has established a new standard of care for first-line systemic therapy of advanced hepatocellular carcinoma @NEJM https://t.co/SJJckuge4E
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/BdM1OHYWgV
Answer: Atezo/Bev Phase 3 RCT showed that Atezolizumab/Bevacizumab resulted in better PFS overall survival compared to the existing standard of care at that time Sorafenib. EGD is recommended to rule out untreated varices Reference: https://t.co/f1L4sbd5Il https://t.co/eUaDoBPqrS
@veronicanguyen @serperm @penngihep Wow we were JUST talking about the complexities of #HCC thanks @veronicanguyen A good review here too from @NEJM : https://t.co/tnI73ZgI7M Learned about this 2020 paper- combo immunotx for unresectable HCC: https://t.co/VBeJrgh3ZI Thanks to @liverprof
RT @SocSurgOnc In this clip from SurgOnc Today™ Marcus Tan, MD gives some of the key findings from "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma." Hear Alexander Parikh, MD and Marcus Tan, MD discuss several #HPB practice ch… https://t.co/P7wGepkbAt
RT @SocSurgOnc: In this clip from SurgOnc Today™ Marcus Tan, MD gives some of the key findings from "Atezolizumab plus Bevacizumab in Unres…
In this clip from SurgOnc Today™ Marcus Tan, MD gives some of the key findings from "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma." Hear Alexander Parikh, MD and Marcus Tan, MD discuss several #HPB practice changing papers at https://t.co/CCJqxRr6Zp. https://t.co/zrS9oREOFJ
RT @HCC_HUNTER: A very exciting study was just published in @NEJM showing that in patients with unresectable #HCC, a new treatment combinat…
RT @AmiBPatelMD: Today was #FellowsJournalClub @huntsmancancer! Here are the @NEJM papers @ChrisNevala and @WAkerleyMD discussed. Thank yo…
Today was #FellowsJournalClub @huntsmancancer! Here are the @NEJM papers @ChrisNevala and @WAkerleyMD discussed. Thank you both! Happy reading! @UtahHemeOnc https://t.co/KADgm7FGlX https://t.co/6yLXWBXiJY
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @jturnesv: Nice discussion in @Plenary_Session between @VPrasadMDMPH & @DrKarineTawagi on IMbrave150 RCT for hepatocellular carcinoma (h…
Nice discussion in @Plenary_Session between @VPrasadMDMPH & @DrKarineTawagi on IMbrave150 RCT for hepatocellular carcinoma (https://t.co/WekNy2KUXw): ➡️https://t.co/AZHKstzH4g ➡️https://t.co/so6qq0nARd Worth listening to it (starts at 1:25:00) #livertwitter #HCC
RT @Dr_JJ_Berenguer: #Atezolizumab plus #Bevacizumab in Unresectable #Hepatocellular Carcinoma #increases #OS and #PFS compared with #soraf…
Excited. My first patient today being treated with new #Immunotherapy combination for liver cancer (HCC). Eye wateringly expensive but a game changer in HCC. And so much better tolerated than sorafenib. https://t.co/wz9vaq0pvC
⚠️ Atezolizumab + Bevacizumab en hepatocarcinoma irresecable: *️⃣ Estudio abierto, randomizado 2:1 para atezo + beva
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
RT @joaprimo: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma: @GiJournal discussion summary #GIJC #livertwitter
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma: @GiJournal discussion summary #GIJC #livertwitter
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
RT @GiJournal: What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #…
What an amazing start to the new and improved #GIJC. We are really excited to post the article and discussion summary for #GIJC discussion on @NEJM article https://t.co/D1TGKgxiZX. Special thanks to @AtoosaRabiee @LizzieAbyMD @jturnesv @SeragHashem https://t.co/g6TMCl7eeU
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: ⭐️Conclusions⭐️ Atezolizumab plus bevacizumab (vs sorafenib) resulted in significantly better overall survival and progres…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @GiJournal: The new #GIJC is starting off with a bang
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @GiJournal: The new #GIJC is starting off with a bang
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @GiJournal: The new #GIJC is starting off with a bang
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: ⭐️ Conclusions ⭐️ Atezolizumab plus bevacizumab (vs sorafenib) resulted in significantly better overall survival and progr…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: ⭐️ Conclusions ⭐️ Atezolizumab plus bevacizumab (vs sorafenib) resulted in significantly better overall survival and progr…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
⭐️Conclusions⭐️ Atezolizumab plus bevacizumab (vs sorafenib) resulted in significantly better overall survival and progression free survival in patients with unresectable HCC without prior systemic treatment https://t.co/TrdwCejYKI #livertwitter #GIJC
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al. Expert opinion: @SeragHashem Moderators: @AtoosaRabiee @jturnesv https://t.co/TrdwCejYKI #livertwitter #GIJC #hpbcsm
For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al. Expert opinion: @SeragHashem Moderators: @AtoosaRabiee @jturnesv https://t.co/TrdwCejYKI #livertwitter #GIJC #hpbcsm
RT @LizzieAbyMD: For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 tria…
⭐️ Conclusions ⭐️ Atezolizumab plus bevacizumab (vs sorafenib) resulted in significantly better overall survival and progression free survival in patients w/unresectable HCC without prior systemic treatment https://t.co/TrdwCejYKI #GIJC #livertwitter
For #GIJournalClub – we will discussing the @NEJM article: Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al. Expert opinion: @SeragHashem Moderators: @AtoosaRabiee @jturnesv https://t.co/TrdwCejYKI #livertwitter #GIJC #hpbcsm
RT @GiJournal: The new #GIJC is starting off with a bang
RT @mqkMD:
RT @GiJournal: The new #GIJC is starting off with a bang
RT @GiJournal: The new #GIJC is starting off with a bang
RT @LizzieAbyMD: Join me on Wednesday at 9pm ET for GI Journal club to discuss Atezolizumab+Bevacizumab for unresectable #HCC! Honored to b…
RT @jturnesv: Esta noche, en la nueva sesión de #GIJC, tenemos un artículo reciente que ha revolucionado el tratamiento del cáncer de hígad…
RT @GiJournal: The new #GIJC is starting off with a bang
RT @mqkMD:
RT @mqkMD:
RT @jturnesv: Esta noche, en la nueva sesión de #GIJC, tenemos un artículo reciente que ha revolucionado el tratamiento del cáncer de hígad…
RT @GiJournal: The new #GIJC is starting off with a bang
Esta noche, en la nueva sesión de #GIJC, tenemos un artículo reciente que ha revolucionado el tratamiento del cáncer de hígado ➡️ https://t.co/I4HkNxfQ7W Moderada por @LizzieAbyMD & @AtoosaRabiee, y con la participación de @SeragHashem
RT @GiJournal: The new #GIJC is starting off with a bang
RT @GiJournal: The new #GIJC is starting off with a bang
RT @GiJournal: The new #GIJC is starting off with a bang
RT @GiJournal: The new #GIJC is starting off with a bang
RT @GiJournal: The new #GIJC is starting off with a bang
RT @LizzieAbyMD: Join me on Wednesday at 9pm ET for GI Journal club to discuss Atezolizumab+Bevacizumab for unresectable #HCC! Honored to b…
RT @LizzieAbyMD: Join me on Wednesday at 9pm ET for GI Journal club to discuss Atezolizumab+Bevacizumab for unresectable #HCC! Honored to b…
RT @SurgMBA: Do we have a new standard? Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/5FHu8cw…
RT @SurgMBA: Do we have a new standard? Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/5FHu8cw…
RT @SurgMBA: Do we have a new standard? Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/5FHu8cw…
Do we have a new standard? Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/5FHu8cwLiO @DrAhmedAlShehri @marwanalhajeili @Abudanaturki @alshamsi2000 https://t.co/ozCQMzV2Ti
RT @SkyscapeInc: Today's MedBeats: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular #Carcinoma #Oncology # #Hepatologist #Inter…
Today's MedBeats: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular #Carcinoma #Oncology # #Hepatologist #InternalMedicine https://t.co/tEG47ESlJI
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/d6YXOUrPdm 간암에서도 면역 치료제 승인. 위험도 감소가 42%이긴 한데...
Excited about the potential for better survival than with sorafenib as first line. After 10 years! #HCC Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/d6eMhnTwYL
RT @UqbaKhan: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM #LiverCancer #Immunotherapy https://t.co/6EY6U…
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @GABOUALFA: Disruptive Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma by @GABOUALFA @practiceupdate available a…
RT @GABOUALFA: Disruptive Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma by @GABOUALFA @practiceupdate available a…
RT @GABOUALFA: Disruptive Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma by @GABOUALFA @practiceupdate available a…
RT @GABOUALFA: Disruptive Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma by @GABOUALFA @practiceupdate available a…
RT @GABOUALFA: Disruptive Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma by @GABOUALFA @practiceupdate available a…
RT @GABOUALFA: Disruptive Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma by @GABOUALFA @practiceupdate available a…
Disruptive Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma by @GABOUALFA @practiceupdate available at: https://t.co/UC0GCKvpg6.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/pUyNmBKuzL
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | @NEJM https://t.co/IeKUCk9XqM #ICI #PDL1i #VEGFi #HCC https://t.co/mLOad2Kt3S https://t.co/lGnPIetBlL
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @deLiguoriCarino: Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular Carcinoma offers longer #OS and #DFS compared to SORAFEN…
RT @drliuhao: This is a BIG breakthrough!! Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/mvIc4…
Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular Carcinoma offers longer #OS and #DFS compared to SORAFENIB NEJM https://t.co/UUJocnlCWi
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
This is a BIG breakthrough!! Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/mvIc4v6knK
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al.; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382: 1894-905. https://t.co/wVfHRsvSIH #Atezolizumab #Bevacizumab #Unresec…https://t.co/0TNBq3K1M6
RT @CellworksLife: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. #HCC #DrugsCancer https://t.co/verimL7GIv
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. #HCC #DrugsCancer https://t.co/verimL7GIv
#Atezolizumab plus #Bevacizumab in Unresectable #Hepatocellular Carcinoma #increases #OS and #PFS compared with #sorafenib https://t.co/xPpvWtqpzY https://t.co/WPRi65TWk0
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/Zy72yXWjrc
RT @DoubleParr: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. | N Engl J Med | " ... combination of anti-PD-L…
RT @DoubleParr: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. | N Engl J Med | " ... combination of anti-PD-L…
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. | N Engl J Med | " ... combination of anti-PD-L1 and anti-VEGF therapy resulted in significantly longer overall and progression-free survival as well as strikingly better... " https://t.co/x86ggLevKT
RT @gedefo_sefh: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma https://t.co/duGGtFPxFc
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma https://t.co/rC0nlo2A46 https://t.co/6TAkrYSDc7
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma https://t.co/duGGtFPxFc
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular #Carcinoma | NEJM https://t.co/tBlpVS27DD
RT @irodriguezpenin: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/o6ZBiSCTuO
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/FXg1RuRrbc
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma https://t.co/sm5BJnZfb0
RT @SyedAAhmad5: New treatment for HCC. @DavendraSohal @shimulshah73 @SWOG @AmericanCancer Atezolizumab plus Bevacizumab in Unresectable He…
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM "better overall & progression-free survival outcomes than sorafenib" https://t.co/JZS1UNyHvC
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/ixoYZVyHHv
RT @irodriguezpenin: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/o6ZBiSCTuO
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/o6ZBiSCTuO
RT @PerelloChristie: New standard of care for advanced HCC patients! @NEJM #movingforward #hope Atezolizumab plus Bevacizumab in Unresecta…
Atezolizumab/Bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. https://t.co/zemqX5Mo5n
RT @StevenSRaman_MD: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM. Congratulations to @UCLA Richard Finn…
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @UqbaKhan: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM #LiverCancer #Immunotherapy https://t.co/6EY6U…
RT @GillSharlene: IMbrave150 finally published! A new 1L standard for advanced HCC - HR OS 0.58, p<0.0001 with more manageable toxicity pr…
RT @PerelloChristie: New standard of care for advanced HCC patients! @NEJM #movingforward #hope Atezolizumab plus Bevacizumab in Unresecta…
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. https://t.co/VmbS4DbBE2
RT @PerelloChristie: New standard of care for advanced HCC patients! @NEJM #movingforward #hope Atezolizumab plus Bevacizumab in Unresecta…
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @PerelloChristie: New standard of care for advanced HCC patients! @NEJM #movingforward #hope Atezolizumab plus Bevacizumab in Unresecta…
RT @BMnguez: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/4YrLlIb4E8
New treatment for HCC. @DavendraSohal @shimulshah73 @SWOG @AmericanCancer Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/Zz2G5pA9Jb
New standard of care for advanced HCC patients! @NEJM #movingforward #hope Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/UHm5cYtRxN
RT @GIcancerDoc: Practice changing ! Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7n…
RT @BMnguez: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/4YrLlIb4E8
RT @BMnguez: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/4YrLlIb4E8
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/bKeA4GMBkJ
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM. Congratulations to @UCLA Richard Finn and colleagues on this landmark study on #HCC @HccTagConf https://t.co/0U7qWAJKKb
RT @BMnguez: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM https://t.co/4YrLlIb4E8
LM
GC
GA
AG
CP
MH
RO
BW
C
จอ
TM
KO
TS
KJ
P
JR
MB
JF
DB
MV
RC
JF
DM
BP
C
T
AK
PO
TM
CC
MO
TM
أا
BC
DS
SA
JD
XX
か
SC
JB
EM
NH
JD
HR
ND
CM
JF
SO
UF
AM
KW
KM
JT
JP
AG
RB
CS
RS
JM
QF
SF
DF
JP
KP
MM
AH
AM
DC
AP
LD
JG
HO
PD
NR
SM
HF
OS
RG
AG
JG
NS
PM
SF
SB
ÁG
VP
LL
FE
سا
أأ
ك
دA
DH
S
정
JP
NH
LH
SL
RT
CA
MH
TP
CF
AP
MT
FC
NC
KT
HL
M
C
C
VF
SA
YO
JR
IK
J
RK
G
LC
AR
JF
YF
IG
MM
BS
IP
CP
JT
HC
VB
AS
D
R
HH
TM
CW
EF
K
JC
早夏
M
PP
SS
SF
OS